Do you want to read an article? Please log in or register.
Impact of mild-to-moderate exacerbations on outcomes of neuromuscular electrical stimulation (NMES) in patients with COPD
COPD
RECOMMENDED
Related content
COPD
Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD
Respir Res.
Leitao Filho FS, Ra SW, Mattman A, Schellenberg RS, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, Leung JM, Paul Man SF, Aaron SD, Reed RM, Sin DD; Canadian Respiratory Research Network (CRRN)
doi: 10.1186/s12931-018-0733-z.
Impact of hyponatremia on mortality and morbidity in patients with COPD exacerbations
Respir Med.
Chalela R, González-García JG, Chillarón JJ, Valera-Hernández L, Montoya-Rangel C, Badenes D, Mojal S, Gea J.
doi: 10.1016/j.rmed.2016.05.003
RECOMMENDED
COPD
Susceptibility to frequent exacerbation in COPD patients: Impact of the exacerbations history, vaccinations and comorbidities?
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med.
Ouaalaya EH, Falque L, Dupis JM, Sabatini M, Bernady A, Nguyen L, Ozier A, Nocent-Ejnaini C, Le Guillou F, Molimard M, Zysman M, Raherison-Semjen C
doi: 10.1016/j.rmed.2020.106018.
COPD
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Int J Chron Obstruct Pulmon Dis.
Beeh KM, Beier J, Candler H, Wittig T
doi: 10.2147/COPD.S11765
RECOMMENDED
COPD
Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
JAMA
Jiménez D, Agustí A, Tabernero E, Jara-Palomares L, Hernando A, Ruiz-Artacho P, Pérez-Peñate G, Rivas-Guerrero A, Rodríguez-Nieto MJ, Ballaz A, Agüero R, Jiménez S, Calle-Rubio M, López-Reyes R, Marcos-Rodríguez P, Barrios D, Rodríguez C, Muriel A, Bertoletti L, Couturaud F, Huisman M, Lobo JL, Yusen RD, Bikdeli B, Monreal M, Otero R, SLICE Trial Group.
doi: 10.1001/jama.2021.14846
RECOMMENDED
COPD
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
Respir Res.
Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, Shen S, Goyal P, Mezzi K, Kostikas K
doi: 10.1186/s12931-019-0972-7.
Asthma
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Respir Med.
Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators
doi: 10.1016/
RECOMMENDED
COPD
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA
doi: 10.1177/1753466620963021
RECOMMENDED
COPD
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C
doi: 10.1186/s12931-020-01388-y.